Regulatory & Legal

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A landmark green ammonia project in Spain offers a blueprint for industrial decarbonization, holding key strategic lessons for the biopharmaceutical sector.

A moving company hosts a governor, revealing the complex logistics and infrastructure network profiting from America's massive wealth redistribution.

VEON and Starlink's landmark satellite call in Kazakhstan isn't just a tech feat; it's an investment blueprint for the future of remote luxury.

The infrastructure giant's new €800M share repurchase isn't just for shareholder value; it's a strategic move to fund future growth and acquisitions.

Beyond a simple date change for its $10M dividend, Dominari Holdings is signaling a major strategic shift, funded by investment gains and aimed at AI.

AIP Realty Trust's $78.7M acquisition of AllTrades pivots on a complex related-party deal and reverse takeover, putting unitholder trust to the test.

indie Semiconductor is aggressively using stock grants to lure top engineers for its ADAS future. But what is the cost of this talent war for investors?

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

Hedge fund Balyasny Asset Management builds a 1.72% stake in JTC plc, signaling high-stakes maneuvering in the £2.3 billion takeover saga.

A routine filing by hedge fund Balyasny Asset Management may have just put Avadel Pharmaceuticals in the M&A spotlight. Here's what the signal means.

Nordic American Tankers is riding a wave of record profits, but the industry's future hinges on volatile markets and the shadow of Venezuelan oil.

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

A novel drug for alcohol use disorder gets key scientific backing. It promises the benefits of psychedelics with fewer risks, shaking up a $35B market.

Fresh off its IPO, iOThree is pushing AI and certified digital tools. Can its innovation engine and Asian expansion overcome market headwinds?

A junior miner is fast-tracking gold and critical metals production in Québec by reviving a key mill. Is this a strategic supply chain win or just savvy promotion?

With over 123 million displaced, refugee camps are now de facto cities. Temporary water solutions are fueling disease, making the case for permanent fixes.